Repare Therapeutics Inc. (RPTX)

NASDAQ: RPTX · Real-Time Price · USD
1.560
+0.010 (0.65%)
At close: Jul 25, 2025, 4:00 PM
1.570
+0.010 (0.64%)
After-hours: Jul 25, 2025, 6:39 PM EDT
0.65%
Market Cap66.91M
Revenue (ttm)1.07M
Net Income (ttm)-127.89M
Shares Out 42.89M
EPS (ttm)-3.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume101,584
Open1.560
Previous Close1.550
Day's Range1.545 - 1.580
52-Week Range0.890 - 4.220
Beta0.84
AnalystsStrong Buy
Price Target4.50 (+188.46%)
Earnings DateAug 5, 2025

About RPTX

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 c... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 19, 2020
Employees 129
Stock Exchange NASDAQ
Ticker Symbol RPTX
Full Company Profile

Financial Performance

In 2024, Repare Therapeutics's revenue was $53.48 million, an increase of 4.58% compared to the previous year's $51.13 million. Losses were -$84.69 million, -9.71% less than in 2023.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for RPTX stock is "Strong Buy." The 12-month stock price target is $4.5, which is an increase of 188.46% from the latest price.

Price Target
$4.5
(188.46% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it has entered into an e...

12 days ago - Business Wire

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results for the...

2 months ago - Business Wire

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

VANCOUVER--(BUSINESS WIRE)--DCx Biotherapeutics Corporation (“DCx”) today announced an agreement with Repare Therapeutics Inc. (“Repare”) (NASDAQ: RPTX) to (i) in-license Repare's discovery platform i...

3 months ago - Business Wire

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its disc...

3 months ago - Business Wire

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance o...

3 months ago - Business Wire

Repare Therapeutics Announces Leadership Transitions

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that Steve Forte...

4 months ago - Business Wire

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

5 months ago - Business Wire

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results.

5 months ago - Business Wire

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions.

7 months ago - Business Wire

Why Is Repare Therapeutics Stock Trading Lower On Friday?

On Thursday, Repare Therapeutics Inc RPTX revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cance...

8 months ago - Benzinga

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Ph1 Gynecologic Expansion Clinical Trial.

8 months ago - Business Wire

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial.

8 months ago - Business Wire

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib.

9 months ago - Business Wire

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results.

9 months ago - Business Wire

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial.

9 months ago - Business Wire

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor.

10 months ago - Business Wire

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting.

10 months ago - Business Wire

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers.

10 months ago - Business Wire

Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the Company will...

11 months ago - Business Wire

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data

Repare Therapeutics Inc. results from phase 1 MYTHIC study, using lunresertib + camonsertib for the treatment of platinum-resistant ovarian and endometrial cancer with genomic alterations, are expecte...

11 months ago - Seeking Alpha

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio.

11 months ago - Business Wire

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics to Participate in Two Upcoming Investor Conferences.

11 months ago - Business Wire

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results...

1 year ago - Business Wire

Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI.

1 year ago - Business Wire

Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib

BOSTON--(BUSINESS WIRE)--Foundation Medicine announces a collaboration with Repare Therapeutics to provide genomic profiling for Repare's ongoing Phase I/Ib MYTHIC study.

1 year ago - Business Wire